TIZIANA LIFE SCIENCES LTD
TLSANASDAQTrading Snapshot
- Day Range
- $0.95 – $0.96
- 52-Week Range
- $0.76 – $2.33
- Volume
- $3.56B
- Avg Volume
- $2.61B
- Shares Outstanding
- 63.6M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- -4.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.38
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.0%
Why Investors Own TLSA
- ✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TIZIANA LIFE SCIENCES LTD
TLSA
StockOtter · stockotter.spaceAbout TIZIANA LIFE SCIENCES LTD
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral sclerosis (ALS). The Healey
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal fo
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment
Dow climbs as stocks rebound on earnings, falling Treasury yields
3:40pm: Small cap wrap Tiziana Life Sciences Ltd (NASDAQ:TLSA) received a Buy rating and $7 price target from BTIG, which highlighted its nasal anti-CD3...
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Ph